Evidence map›Paper›PMID 40106334›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

ROS-Driven Nanoventilator for MRSA-Induced Acute Lung Injury Treatment via In Situ Oxygen Supply, Anti-Inflammation and Immunomodulation.

Zheng Luo, Qi Wang, Xiaotong Fan, Xue Qi Koh, Xian Jun Loh, Caisheng Wu, Zibiao Li, Yun-Long Wu

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zheng LuoState Key Laboratory of Cellular Stress Biology, Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen, 361102, China.
Qi WangState Key Laboratory of Cellular Stress Biology, Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen, 361102, China.
Xiaotong FanInstitute of Sustainability for Chemicals, Energy and Environment (ISCE2), Agency for Science, Technology and Research (A*STAR), 1 Pesek Road, Jurong Island, Singapore, 627833, Republic of Singapore.
Xue Qi KohInstitute of Materials Research and Engineering (IMRE), Agency for Science, Technology and Research (A*STAR), 2 Fusionopolis Way, Innovis #08-03, Singapore, 138634, Republic of Singapore.
Xian Jun LohInstitute of Materials Research and Engineering (IMRE), Agency for Science, Technology and Research (A*STAR), 2 Fusionopolis Way, Innovis #08-03, Singapore, 138634, Republic of Singapore.
Caisheng WuState Key Laboratory of Cellular Stress Biology, Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen, 361102, China.
Zibiao LiInstitute of Materials Research and Engineering (IMRE), Agency for Science, Technology and Research (A*STAR), 2 Fusionopolis Way, Innovis #08-03, Singapore, 138634, Republic of Singapore.ORCID https://orcid.org/0000-0002-0591-5328
Yun-Long WuState Key Laboratory of Cellular Stress Biology, Fujian Provincial Key Laboratory of Innovative Drug Target Research, School of Pharmaceutical Sciences, Xiamen University, Xiamen, 361102, China.

Funding

Agency for Science, Technology, and ResearchNational Key Research and Development Program of China 2020YFA0908100Natural Science Foundation of China 81971724Natural Science Foundation of China 82141215Natural Science Foundation of China 82173750Science and Engineering Research Council
6 · The paper itself

Abstract

Hypoxia, inflammatory response and pathogen (bacterial or viral) infection are the three main factors that lead to death in patients with acute lung injury (ALI). Among them, hypoxia activates the expression of HIF-1α, further exacerbating the production of ROS and inflammatory response. Currently, anti-inflammatory and pathogen elimination treatment strategies have effectively alleviated infectious pneumonia, but improving lung hypoxia still faces challenges. Here, a vancomycin-loaded nanoventilator (SCVN) containing superoxide dismutase (SOD) and catalase (CAT) is developed, which is prepared by encapsulating SOD, CAT and vancomycin into a nanocapsule by in situ polymerization. This nanocapsule can effectively improve the stability and loading rate of enzymes, and enhance their enzyme cascade efficiency, thereby efficiently consuming •O

Indexed as

Acute Lung InjuryAnti-Inflammatory AgentsMethicillin-Resistant Staphylococcus aureusReactive Oxygen SpeciesStaphylococcal InfectionsAnimalsCatalaseDisease Models, AnimalImmunomodulationMaleMiceOxygenSuperoxide DismutaseVancomycinAnti-Inflammatory AgentsCatalaseOxygenReactive Oxygen SpeciesSuperoxide DismutaseVancomycinacute lung injuryanti‐inflammatoryenzyme therapyoxygen supplyROS clearance

Identifiers

PMID40106334
PMCPMC12079454

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.